A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).

Abstract

BACKGROUND:

Although paclitaxel was given triweekly in phase II trials prior to its approval for gastric cancer in Japan, it is currently more often delivered by a weekly schedule in the second-line setting.

PATIENTS AND METHODS:

A phase II trial with response rate as the primary end-point was conducted. Patients with metastatic or unresectable gastric adenocarcinoma who had measurable lesions and had disease progression with the front-line chemotherapy were treated by weekly administration of paclitaxel at a dose of 80 mg/m2.

RESULTS:

Forty-five patients were accrued and 44 were assessable for response. Partial responses were observed in 7 patients (16%). Stable disease was documented in further 14 patients (48%). Median progression-free survival of all patients enrolled was 2.6 months and median overall survival was 7.8 months. Toxicity was mild and manageable, the most frequent > or = grade 3 toxicity being neutropenia occurring in 16% of the patients.

CONCLUSION:

With modest response rate, favorable toxicity profile, and progression-free or overall survival similar to those of more intense combination regimens, weekly paclitaxel remains a rational therapeutic option for gastric cancer refractory to the first-line chemotherapy.

• Authors: Yasuhiro Kodera, Seiji Ito, Yoshinari Mochizuki, Shinichi Fujitake, Katsumi Koshikawa, Yasuaki Kanyama, Takanori Matsui, Hiroshi Kojima, Tsunenobu Takase, Norifumi Ohashi, Michitaka Fujiwara, Junichi Sakamoto, Nakao Akimasa, Chubu Clinical Cancer Group
• Journal: Anticancer research (Anticancer Res) 2007 Jul-Aug Vol. 27 Issue 4C Pg. 2667-71 ISSN: 0250-7005 [Print] Greece
• PMID: 17695430 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Paclitaxel

Topics

• Adenocarcinoma (drug therapy)
• Aged
• Antineoplastic Agents, Phytogenic (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Paclitaxel (administration & dosage)
• Stomach Neoplasms (drug therapy)